Autoimmune liver diseases (AILDs) are chronic liver pathologies characterized by fibrosis and cirrhosis due to immunemediated liver damage. In this study, we addressed the question whether mucosal-associated invariant T (MAIT) cells, innate-like T cells, are functionally altered in patients with AILD and whether MAIT cells can promote liver fibrosis through activation of hepatic stellate cells (HSCs). We analyzed the phenotype and function of MAIT cells from AILD patients and healthy controls by multicolor flow cytometry and investigated the interaction between human MAIT cells and primary human hepatic stellate cells (hHSCs). We show that MAIT cells are significantly decreased in peripheral blood and liver tissue of patients with AILD. Notably, MAIT cell frequency tended to decrease with increasing fibrosis stage. MAIT cells from AILD patients showed signs of exhaustion, such as impaired interferon-c (IFN-c) production and high ex vivo expression of the activation and exhaustion markers CD38, HLA-DR, and CTLA-4. Mechanistically, this exhausted state could be induced by repetitive stimulation of MAIT cells with the cytokines interleukin (IL)-12 and IL-18, leading to decreased IFN-c and increased exhaustion marker expression. Of note, repetitive stimulation with IL-12 further resulted in expression of the profibrogenic cytokine IL-17A by otherwise exhausted MAIT cells. Accordingly, MAIT cells from both healthy controls and AILD patients were able to induce an activated, proinflammatory and profibrogenic phenotype in hHSCs in vitro that was partly mediated by IL-17. Conclusion: Our data provide evidence that MAIT cells in AILD patients have evolved towards an exhausted, profibrogenic phenotype and can contribute to the development of HSC-mediated liver fibrosis. These findings reveal a cellular and molecular pathway for fibrosis development in AILD that could be exploited for antifibrotic therapy. (HEPATOLOGY 2018;68:172-186).
M ucosal-associated invariant T (MAIT) cells are innate-like T cells characterized by an evolutionarily conserved semi-invariant T cell receptor (TCR) consisting of an invariant a chain (Va7.2-Ja33/Ja20/Ja12 in humans) and varying b chains, (1, 2) as well as high expression of the C-type lectin CD161. (3) Human MAIT cells are abundant in peripheral blood, but particularly enriched in liver tissue, representing up to 30% of hepatic CD3 1 T cells. (3, 4) The ability of MAIT cells to recognize microbial-derived vitamin B metabolites presented on the major histocompatibility complex class I-related Abbreviations: AIH, autoimmune hepatitis; AILD, autoimmune liver disease; ANOVA, analysis of variance; HSC, hepatic stellate cell; hHSC, primary human hepatic stellate cell; IFN-c, interferon-c; IL, interleukin; MAIT cell, mucosal-associated invariant T cell; PBC, primary biliary cholangitis; NASH, nonalcoholic steatohepatitis; PBMC, peripheral blood mononuclear cell; PMA, phorbol 12-myristate 13-acetate; PSC, primary sclerosing cholangitis; RORcT, retinoic acid-related orphan receptor cT; SD, standard deviation; SEM, standard error of the mean; STAT, signal transducer and activator of transcription; TCR, T cell receptor; TIMP-1, tissue inhibitor of metalloproteinase 1; TNF-a, tumor necrosis factor a. molecule MR1 (5) allows MAIT cells to detect various strains of bacteria and yeasts in vitro and in vivo. (6, 7) In line with their innate-like nature, MAIT cells are also activated by the proinflammatory cytokines interleukin (IL)-12 and IL-18 in a TCR-independent manner. (8) Once activated, MAIT cells exert cytotoxic properties and secrete proinflammatory cytokines such as IL-17 and IFN-c. (3, 6) In addition to their role in mediating antimicrobial defense, MAIT cells have been implicated in the development of noninfectious diseases, including autoimmune diseases such as multiple sclerosis (9, 10) and inflammatory bowel disease, (11) suggesting that MAIT cells can orchestrate inflammatory responses in absence of infection. Autoimmune liver diseases (AILD) (e.g., primary sclerosing cholangitis [PSC] , primary biliary cholangitis [PBC] , and autoimmune hepatitis [AIH] ) are characterized by chronic hepatic inflammation, which eventually leads to the development of liver fibrosis and cirrhosis and is associated with a high risk of morbidity and mortality. (12) The pathogenesis of AILD is poorly understood, although it is becoming increasingly clear that environmental triggers and genetic aberrations of immunoregulatory pathways contribute to chronic inflammation and T cell-mediated damage in the liver. (12) Genome-wide association studies recently demonstrated that variations in the IL-12 pathway are associated with the development of PBC. (13) A potential role of IL-12 in AILD development is further supported by murine studies, in which deletion of the IL-12 subunit p40 ameliorated the development of autoimmune cholangitis, (14) and overexpression of IL-12 resulted in development of an AIH-resembling liver inflammation. (15) Central to the development of liver fibrosis by inflammation is the activation of hepatic stellate cells (HSCs), nonparenchymal liver cells that transform into extracellular matrix secreting myofibroblasts following activation. (16) HSC activation and the subsequent development of liver fibrosis are mediated by IL-17 in murine models, evident by ameliorated liver fibrosis in IL-17RA 2/2 mice in vivo, as well as increased collagen secretion and expression of a smooth muscle actin, IL-6, and transforming growth factor b by IL-17-stimulated HSCs in vitro. (17, 18) However, whether MAIT cell-derived IL-17A can mediate HSC activation in humans remains unclear. Here, we investigated the role of human MAIT cells in fibrosis development and HSC activation in AILD. Our data show that MAIT cells are severely reduced in peripheral blood and liver tissue from AILD patients, and the remaining MAIT cells show features of chronic activation and functional exhaustion, which could be induced by long-term exposure to the proinflammatory cytokines IL-12 and IL-18. Despite their exhausted state, MAIT cells produce large amounts of IL-17A in response to repetitive stimulation with IL-12. MAIT cells are further able to activate HSCs, leading to HSC proliferation and the expression of profibrogenic and proinflammatory genes in HSCs in an IL-17 and cell-cell contact dependent manner. Our data reveal a crucial role of MAIT cells in liver fibrosis development and provide important mechanistic insights that will help to design novel therapeutic approaches targeting HSC activation in fibrosis.
Material and Methods
A complete description of the materials and methods used in this study is provided in the Supporting Information.
ETHICS STATEMENT
This study was fully approved by the Royal Free Hospital ethical board. All participants provided written informed consent before sample collection.
PRIMARY CELL ISOLATION
All tissue samples were obtained from patients or healthy volunteers at the Royal Free Hospital (see Supporting Table S1 for patient information). Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) gradient centrifugation. Liver-associated lymphocytes were isolated from cirrhotic liver tissue derived from explanted livers of patients with AILD, from wedge sections of patients undergoing liver surgery in the absence of background liver disease, or from healthy liver explants considered unsuitable for transplantation (enabled by NHSBT). Primary human HSCs (hHSCs) were isolated from wedge sections of human liver tissue as described previously. (19) FLOW CYTOMETRIC ANALYSIS Cells were stained for surface markers and intracellular markers (see Supporting Information for a full list of antibodies). Dead cells were excluded using a live/ dead fixable UV dead cell stain kit (Invitrogen, Carlsbad, CA). For staining of intracellular markers, cells were fixed and permeabilized using an Intracellular 
TRANSIENT ELASTOGRAPHY
Transient elastography was performed to measure liver stiffness using FibroScan (Echosens, Waltham, MA). Fibrosis stage was defined using the previously described cutoffs for stiffness: F0-1, <7.1 kPa; F2, 7.1-9.4 kPa; F3, 9.5-12.4 kPa; F4, >12.5 kPa. (20) . Data are presented as the mean 6 SD and were pooled from four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus healthy controls (HC). Data were assessed using one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test (a, d) or Mann-Whitney test (b, c, e). ns, not significant.
IN VITRO STIMULATION ASSAYS
significantly decreased in peripheral blood of patients with nonalcoholic steatohepatitis (NASH) ( 1 MAIT cells represented the major subset in peripheral blood and liver tissue of healthy controls and AILD patients ( Fig. 1d-e) , although a relative increase of CD4
1 MAIT cells was observed ( Fig. 1d-e) in AILD patients. Moreover, the frequency of MAIT cells in peripheral blood of AILD patients decreased with increasing fibrosis stage and liver tissue stiffness assessed by transient elastography (Fig. 1f) , suggesting that the frequency of MAIT cells declines with disease progression in AILD. To analyze the localization of MAIT cells in the liver, Va7.2 TCR was immunohistochemically detected in liver tissue of patients and controls. Whereas MAIT cells localized around the portal tracts and in the parenchyma in normal livers (Fig. 2a) , MAIT cells were observed in inflammatory infiltrates around portal tracts and fibrotic septae in diseased livers (Fig. 2a) . Quantification of Va7.2 1 cells revealed a marked decrease of MAIT cell numbers in liver tissue of PSC and PBC patients compared to healthy controls, while MAIT cells were unchanged in highly inflamed AIH and NASH (Fig. 2b) . Taken together, these data establish that the frequency of MAIT cells is severely reduced in peripheral blood and liver tissue of patients with AILD.
MAIT CELLS FROM AILD PATIENTS SHOW FEATURES OF CHRONIC ACTIVATION AND FUNCTIONAL EXHAUSTION
Because AILDs are characterized by chronic inflammation, (12) we next probed MAIT cells from patients with AILD for features of immune activation and exhaustion ex vivo. Whereas the surface expression of the inhibitory receptor PD-1 was comparable in MAIT cells from peripheral blood of patients and healthy controls (Supporting Fig. S2a ), levels of CTLA-4 and TIM-3 were higher in MAIT cells from patients with AILD. Importantly, MAIT cells from AILD patients showed higher expression of CD39, a marker of terminal and irreversible T cell exhaustion. (21) In line with increased expression of exhaustion markers, MAIT cells from patients with AILD showed significantly higher levels of the activation marker CD38 and markedly increased expression of CD69 and HLA-DR (Fig. 3a) , indicating that MAIT cells in peripheral blood of AILD patients are chronically activated. Mirroring the findings in MAIT cells from peripheral blood, hepatic MAIT cells from AILD patients showed significantly higher levels of CTLA-4 compared with healthy controls (Fig. 3b) , while the levels of other activation and exhaustion markers were similar (Supporting Fig. S2b ). Of note, MAIT cells isolated from peripheral blood of NAFLD/NASH patients showed increased expression of the activation and exhaustion markers PD-1, CD39, CD38, and HLA-DR as well (Supporting Fig.  S2c) , suggesting that MAIT cell activation also occurs in nonautoimmune liver disease. Because T cell exhaustion is associated with a loss of effector function, (22) we next assessed the ability of AILD MAIT to produce effector cytokines and cytolytic proteins in response to stimulation. Compared with healthy controls, IFN-c production was significantly impaired in MAIT cells from patients with PBC, and markedly reduced in MAIT cells from patients with PSC and AIH following in vitro stimulation with PMA/ionomycin (Fig. 3c) . Moreover, MAIT cells from AILD patients showed higher granzyme B levels at steady state, but failed to significantly up-regulate granzyme B expression upon CD3/CD28 bead stimulation, compared with healthy controls (Fig. 3d) . In contrast, IL-17A and tumor necrosis factor a (TNF-a) production in response to such stimulation remained unchanged ( Fig. 3e and Supporting Fig. S2d ). These data strongly suggest that MAIT cells in AILD are highly activated and show signs of early functional exhaustion while maintaining their ability to express IL-17A and TNF-a. Correlation analyses further revealed a negative correlation between MAIT cell frequency in AILD and expression of activation markers such as CD38 and HLA-DR as well as exhaustion markers such as CTLA4, CD39, and TIM-3 ( 18R expression on MAIT cells from peripheral blood and liver tissue of healthy controls and AILD patients (Supporting Fig. S3a-b) . AILDs are characterized by persistent liver inflammation and high serum levels of proinflammatory cytokines such as IL-1b, IL-12, and IL-18. (23, 24) We mimicked this chronic inflammatory setting by repetitively stimulating MAIT cells with IL-12, IL-18, and IL-1b in vitro and assessed their ability to express IFN-c. Both short-term (24 hours) and repetitive, long-term (72 hours) in vitro stimulation with a combination of IL-12 and IL-18, but not IL-12 or IL-18 alone, induced a robust IFN-c response in MAIT cells from healthy controls and AILD patients, which was not further exacerbated by additional IL-1b (Fig. 4a) , demonstrating that the response to cytokine-mediated stimulation is maintained in MAIT cells from patients with AILD, despite their exhausted phenotype. To exclude effects from bystander immune cells in the stimulated PBMC pool on the induction of IFN-c expression in MAIT cells, purified Va7.2 1 MAIT cells from healthy controls were stimulated with IL-1b, IL-12, and IL-18 next. Like in PBMCs, IL-12 1 IL-18 specifically induced expression of IFN-c in purified MAIT cells (Fig. 4b) , indicating that IL-12 1 IL-18 can directly stimulate MAIT cell activation. Interestingly, IFN-c expression of MAIT cells from healthy controls and AILD patients significantly decreased following repetitive, long-term stimulation with IL-12 1 IL-18 in vitro (Fig. 4c) , despite constant levels of IL-12 receptor expression (Supporting Fig. S4a ). Because decreasing IFN-c expression is a hallmark of T cell exhaustion, we next tested the expression of inhibitory receptors in cytokine-stimulated MAIT cells. Following repetitive stimulation with IL-12 1 IL-18, we observed increased PD-1 and TIM-3 expression, as well as significantly higher expression of CD39 in MAIT cells from healthy controls (Fig. 4d ) and AILD patients (Supporting Fig. S34b) . Moreover, the frequency of live MAIT cells declined in response to repetitive stimulation with IL-12 1 IL-18, whereas the frequency of CD3 1 cells remained constant (Supporting Fig. S4c) , showing that MAIT cell loss was specific and not accompanied by general T cell death in culture. These data suggest that repetitive stimulation with the proinflammatory cytokines IL-12 1 IL-18 can to drive MAIT cell exhaustion and cell death in vitro. To investigate possible mechanisms of MAIT cell exhaustion in AILD in vivo, we analyzed CD3 expression in hepatic MAIT cells as a surrogate marker for antigen exposure. (25) Indeed, hepatic AILD MAIT cells showed significantly lower expression of CD3 compared with healthy controls (Fig. 4e) , suggesting that MAIT cells are chronically exposed to their cognate antigen in AILD livers in vivo. Of note, exposure to bacterial antigens has been shown to induce downregulation of the transcription factors eomesodermin and T-bet in MAIT cells, which has been linked to MAIT cell exhaustion. (26) We therefore analyzed Tbet and eomesodermin expression in MAIT cells ex vivo. Indeed, MAIT cells from peripheral blood of AILD patients expressed significantly lower levels of eomesodermin and lower levels of T-bet compared with healthy controls (Fig. 4f) . These data suggest that MAIT cell exhaustion in AILD might be induced by chronic exposure to both inflammatory cytokines and bacterial antigen and may be regulated by downregulation of T-bet and eomesodermin.
REPETITIVE IL-12 STIMULATION SIGNIFICANTLY INDUCES THE EXPRESSION OF THE PROFIBROGENIC CYTOKINE IL-17A IN MAIT CELLS
Previous reports have described the induction of IFN-c expression in MAIT cells in a PBMC pool by IL-12 1 IL-18. (8, 27) However, to our knowledge there is no evidence for cytokine-mediated stimulation of IL-17A expression, which has been shown to contribute to fibrosis development in animal models and to stimulate HSC activation in vitro. (17, 18) Interestingly, no IL-17A expression was detected in MAIT cells after short-term (24 hours) cytokine stimulation (Fig.  5a ). In contrast, repetitive, long-term (72 hours) stimulation with IL-12 alone or in combination with other cytokines resulted in a significant increase in IL-17A 1 MAIT cells from healthy controls (Fig. 5b) . Similarly, repetitive stimulation of purified MAIT cells with IL-12 significantly induced IL-17A expression in MAIT cells (Fig. 5c) , demonstrating that the observed IL-17A expression resulted from direct IL-12 signaling on MAIT cells. Along these lines, long-term stimulation with IL-12 induced IL-17A expression in MAIT cells from AILD patients (Fig. 5d) , which was indistinguishable from IL-17A expression in MAIT cells from healthy controls (Fig. 5e) . These data demonstrate that MAIT cells from AILD patients, despite their exhausted phenotype, produce IL-17A in response to repetitive stimulation with inflammatory cytokines. To elucidate a mechanism through which ) and were pooled from at least three independent experiments.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus no stimulation, healthy controls (HC), or as indicated. Data were assessed using two-way ANOVA and Sidak's multiple comparisons test (a-d) or a Mann-Whitney test (e-f). ns, not significant. SD and were pooled from at least two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus no stimulation or as indicated. Data were assessed using two-way ANOVA and Sidak's multiple comparisons test (a-e) or a paired t-test and Kruskal-Wallis test (f).
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IL-12 stimulates IL-17A expression in MAIT cells, we analyzed expression of the transcription factor retinoic acid-related orphan receptor cT (RORct), which is required for the expression of IL-17 in T cells. (28) We detected significantly increased levels of RORct expression in MAIT cells from healthy controls (Fig.  5f ) and AILD patients (Supporting Fig. S5a ) following 24-hour IL-12 stimulation, which was sustained in MAIT cells stimulated for 72 hours ( Fig. 5f and Supporting Fig. S5a ). These data indicate that IL-12 signaling induces robust up-regulation of RORct expression in MAIT cells, which may mechanistically enable IL-17A expression.
MAIT CELLS STIMULATE PRIMARY HUMAN HSC PROLIFERATION AND INDUCE AN ACTIVATED, PROINFLAMMATORY HSC GENE SIGNATURE IN A CELL-CELL CONTACT AND IL-17-DEPENDENT MANNER
Chronic hepatic inflammation in AILD results in the development of liver fibrosis (12) as a consequence of HSC activation, (29) which can be mediated by IL-17A in murine models. (17, 18) As we observed IL-17A expression by MAIT cells upon repetitive stimulation with IL-12, we hypothesized that human MAIT cells are able to activate HSCs in vitro and analyzed hHSC proliferation in the presence of MAIT cells. Coculture of hHSCs with MAIT cells at a ratio of 1:1 resulted in a significant increase in hHSC proliferation (Fig. 6a) . We next investigated gene expression in hHSCs cocultured with MAIT cells. MAIT cells induced increased expression of Acta2, coding for the activation marker a smooth muscle actin in hHSCs, as well as a significant increase in expression of the profibrogenic genes collagen 1, lysyl oxidase (LOX), and tissue inhibitor of metalloproteinase 1 (TIMP-1) (Fig. 6b) . Similarly, expression of proinflammatory genes (e.g., IL-1b, IL-6, IL-8, and CCL2) was significantly increased in hHSCs following 48-hour coculture with MAIT cells (Fig. 6b) . We next investigated whether MAIT cells from AILD patients, although exhausted, were able to increase the expression of genes typical of HSC activation. Similar to MAIT cells from healthy controls, MAIT cells from AILD patients induced gene expression in HSCs regardless of disease type (Fig. 6c) and stimulated hHSC proliferation (Supporting Fig. S6a ), indicating that MAIT cells from AILD patients retain their profibrogenic potential. Of note, MAIT cells isolated from patients with different fibrosis stages showed no difference in their ability to induce hHSC proliferation and gene expression. Moreover, similar to AILD MAIT cells, NASH MAIT cells stimulated proinflammatory gene expression in HSCs (Fig. 6d) . These data indicate that MAIT cells are able to further promote the features of hHSC activation in vitro, a process that contributes to fibrosis development in the liver in vivo. (29) To determine whether IL-17A mediates hHSC activation by MAIT cells, we tested the effect of IL-17RA blockade on hHSC gene expression in our coculture system. Because IL-17 did not induce expression of profibrogenic genes in hHSCs in vitro but was sufficient to induce expression of proinflammatory genes in hHSCs (Supporting Fig. S6b) , we tested the effect of IL-17R blockade on proinflammatory gene expression. Indeed, blocking IL-17R resulted in a decrease of IL-1b, IL-8, and CCL2 expression in hHSCs cocultured with MAIT cells (Fig. 6e) , indicating that hHSC activation by MAIT cells is partly mediated by IL-17A. We next investigated whether hHSC activation by MAIT cells also requires cell-cell contact. MAIT cells and hHSCs were either cocultured allowing for cell-cell contact or in a transwell system, thereby preventing cellular contact but allowing the exchange of soluble mediators. Separation of MAIT cells and hHSCs in the transwell system partly reversed up-regulation of IL-1b, IL-8, and CCL2 expression and abrogated up-regulation of IL-6, LOX, and TIMP-1 expression in HSCs (Fig.  6f) . Taken together, these data suggest that MAIT cells from healthy individuals, as well as from patients with chronic liver disease, can induce hHSC activation in vitro in an IL-17A-and cell-cell contact-dependent manner.
Discussion
The pathogenesis of AILD development is still incompletely understood. However, it has recently become clear that chronic inflammation observed in AILD results from inadequate immune activation and a breakdown of self-tolerance in the liver, culminating in T cell-mediated liver damage and fibrosis development, (12) which is characterized and driven by HSC activation. (29) Here, we demonstrate a potential role of MAIT cells in fibrosis development in AILD. Irrespective of the type of disease, MAIT cells in AILD patients showed phenotypical and functional features of cellular exhaustion and were severely reduced in number. The severe decline of MAIT cells observed in both peripheral blood and liver tissue of AILD patients probably results from chronic activation and cellular exhaustion, which is commonly characterized by a hierarchical loss of effector function, followed by cell death. (30) T cell exhaustion arises from chronic exposure to various stimuli, e.g. chronic infection with pathogens, (31, 32) long-term exposure to viral antigen, (22) antigen-release from tumors, (33) or long-term inflammation and chronic exposure to inflammatory cytokines. (34) Here, we show that exhaustion of human MAIT cells can be driven by long-term stimulation with the proinflammatory, third-signal cytokines IL-12 1 IL-18. Because both IL-12 and IL-18 levels are elevated in serum of patients with AILD, (23, 24) it seems plausible that MAIT cells are chronically exposed to IL-12 1 IL-18 in AILD patients, providing a potential mechanistic explanation for the observed exhaustion of MAIT cell in AILD patients in vivo. Moreover, we show that MAIT cells from AILD patients express significantly lower levels of CD3 as well as of the transcription factor eomesodermin, both of which can be induced by antigen exposure. (25, 26) Thus, it is likely that additional mechanisms such as long-term exposure to bacterialderived antigen contribute to MAIT cell activation and exhaustion in vivo. This is of special importance considering that AILD cirrhosis is often characterized by bacterial translocation from the gut to the liver, (35) which might provide a source of bacterial-derived riboflavin derivatives that specifically activate MAIT cells. (36, 37) The proinflammatory cytokine IL-17A is regarded as a key cytokine for the development of tissue-specific autoimmune disorders and has recently been shown to be involved in hepatic fibrosis development in both non-autoimmune-mediated liver disease (18, 38, 39) and AILD. (13, (38) (39) (40) (41) PSC, PBC, and AIH patients show elevated serum levels of IL-17, (42) (43) (44) along with infiltration of IL-17 1 cells into the liver parenchyma. (42, 45) Furthermore, the number of liver-infiltrating IL-17 1 cells correlates with hepatic inflammation and fibrosis in AIH. (46) Although IL-17 can be secreted by conventional T helper 17 cells at high levels, (47) up to now it is unclear which cells contribute to IL-17 production during human liver inflammation, especially in AILD. Interestingly, MAIT cells represent more than 60% of IL-17 1 cells in the liver, (4) suggesting that IL-17 in the liver in vivo might be predominantly derived from MAIT cells rather than T helper 17 cells. MAIT cells from AILD patients, despite exhibiting clear features of chronic exhaustion, retain their ability to express the cytokine IL-17A ex vivo; therefore, it seems likely that MAIT cells constantly produce IL-17A in the liver of AILD patients. Furthermore, we describe for the first time that chronic stimulation of MAIT cells by the innate, proinflammatory cytokine IL-12 stimulates IL-17A expression in MAIT cells. IL-12 predominantly signals through activation of the transcription factors signal transducer and activator of transcription 1 (STAT1), STAT3, STAT5, and in particular STAT4, (48, 49) leading to IFN-c expression. (50) However, STAT3 signaling can further induce the expression of the transcription factor RORcT, which regulates IL-17 expression (28) and is constitutively expressed in MAIT cells. (3) We show that IL-12 stimulation induces significant up-regulation of RORct in MAIT cells. Therefore, the observed expression of IL-17 in MAIT cells following prolonged exposure to IL-12 might result from "nonclassical" IL-12 signaling, which is mediated through STAT3-regulated RORcT induction, although further experiments are necessary to fully confirm this hypothesis.
Activation of HSCs is a key event in the development of liver fibrosis, because HSCs transform into hyperproliferative, myofibroblast-like cells producing large amounts of extracellular matrix proteins upon activation, thereby leading to the formation of liver fibrosis and cirrhosis. (29) In murine models of liver fibrosis, it has been demonstrated that fibrosis development depends on IL-17A in vivo, and that IL-17A induces HSC activation in vitro. (18) However, whether IL-17 contributes to fibrosis development through activation of HSCs in human AILD has not been investigated so far. Our findings show that MAIT cells induce HSC proliferation and an activated, profibrogenic and proinflammatory phenotype in primary human HSCs in vitro. Interestingly, despite an exhausted phenotype, MAIT cells from AILD patients, regardless of the donor's fibrosis stage, retain their ability to secrete IL-17A and are equally able to induce HSC activation. These data suggest that MAIT cells may contribute to fibrosis development in AILD in vivo throughout disease progression. Moreover, we show that MAIT cells isolated from NASH patients are highly activated and are able to induce HSC activation in vitro as well, suggesting a general profibrogenic role of MAIT cells in chronic liver disease. Mechanistically, the profibrogenic activation of HSCs by MAIT cells depends on IL-17A but also involves direct cell-cell contact between MAIT cells and HSCs, at least in vitro.
Taken together, our findings demonstrate a role for IL-17 producing MAIT cells as profibrogenic cellular mediators in AILD, which could serve as a potential therapeutic target for novel antifibrotic approaches.
